StockGuide AI
Acompanhar ações
EN RU ES DE IT PT FR
Cidara Therapeutics

Cidara Therapeutics

Preço: 221.38

Empresa e modelo de negócios

Cidara Therapeutics is a biotechnology company focused on developing innovative therapeutics for serious fungal infections and other diseases. Its core products include the antifungal agent rezafungin, which is in clinical development for treating invasive fungal infections. The company primarily generates revenue through research and development collaborations and potential future product sales.

Perfil de investimento

The investment profile of Cidara Therapeutics is more aligned with growth investors due to its focus on developing novel therapies in a specialized market. The company currently does not provide dividends, and its financial performance indicates a higher risk profile. Investors should consider the potential for significant returns against the backdrop of inherent volatility in the biotech sector.

Site oficial

Métricas fundamentais (experimental)

EPS (TTM) — lucro por ação dos últimos 12 meses, $
-11.78 Risco
Volatilidade 20d
0.1% estável
Dados FMP / FinFeed atualizados: 2026-06-13
Rec.: Vender Potencial: 30 Risco: 80 Atualizado: 2026-06-13 02:36
Como a recomendação funciona
Por que a IA pensa assim:
Weak fundamentals and high volatility raise significant risk.

Acompanhar no portfólio

Gráfico de preço

Recomendação da IA Previsão do analista Evento de calendário Sinal positivo Sinal negativo Neutro / atualização Manter / informativo B My buy S My sell
Mudanças na recomendação da IA
Data Antes Depois Motivo
2026-05-08 15:06 — Vender Weak fundamentals and high volatility raise significant concerns.
2026-05-08 05:21 Manter Manter Компания показывает значительный рост за последние 60 и 120 дней, но отрицательный EPS и высокая волатильность указывают на высокий риск. Рекомендуется удерживать акции до получения более стабильных финансовых показателе
2026-03-11 05:49 Vender Manter Компания демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и высокая волатильность указывают на риски. Рекомендуется удерживать акции до получения более стабильных финансовых результатов.
Previsões de analistas
Data Analista Action Alvo Preço na época
2025-11-14 21:13 RBC Capital Rating rebaixado — → 221.5 217.71
2025-10-09 14:44 H.C. Wainwright Preço-alvo elevado 110 → 150 108.18
2025-10-03 09:40 JMP Securities Preço-alvo elevado 153 → 173 98.5

Nada ainda